已发表论文

使用基于硼替佐米 (Bortezomib) 的化疗治疗顽固/复发成人急性淋巴细胞白血病

 

Authors Zhao J, Wang C, Song Y, Liu Y, Fang B

Published Date June 2015 Volume 2015:8 Pages 211—214

DOI http://dx.doi.org/10.2147/IJGM.S59537

Received 20 December 2013, Accepted 4 February 2014, Published 12 June 2015

Abstract: Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-positive ALL patients, achieved a complete remission. Furthermore, the evaluable patients have benefited from allo-HSCT after response to this reinduction treatment. We conclude that bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT. Therefore, this regimen deserves a larger series within prospective trials to confirm these results.
Keywords: acute lymphoblastic leukemia, refractory, relapsed, bortezomib